SCHEMBL30003759

SCHEMBL30003759

CC(C)c1nc(-c2ccc(C(F)(F)F)cc2)sc1CCc1noc2cc(N(C)CCO)ccc12

nearest known ligand 0.64

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 13/20 0.64
PPARA Q07869 12/20 0.64
PPARG P37231 7/20 0.64
FFAR1 O14842 4/20 0.33
MAPT P10636 1/20 0.31
SLC9A5 Q14940 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24658612 1.00 PPARD (0.64) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL1765961 0.89 PPARD (0.68) PPARDPPARAPPARGFFAR1
SCHEMBL30003646 0.87 PPARD (0.65) PPARDPPARAPPARGFFAR1
SCHEMBL24742427 0.87 PPARD (0.65) PPARDPPARAPPARGFFAR1
SCHEMBL4034200 0.85 PPARD (0.71) PPARDPPARAPPARGFFAR1
SCHEMBL4030846 0.83 PPARD (0.69) PPARDPPARAPPARGFFAR1
SCHEMBL12732572 0.81 PPARG (0.51) PPARDPPARAPPARG
SCHEMBL4033025 0.80 PPARD (0.73) PPARDPPARAPPARGFFAR1MAPT
SCHEMBL4799607 0.80 PPARG (0.69) PPARDPPARAPPARGFFAR1
SCHEMBL24658290 0.79 PPARD (0.76) PPARDPPARAPPARGMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333379-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2025-10-30 US disclosed
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES ABIONYX PHARMA SA (FR) 2024-06-20 US disclosed
US-11634387-B2 Compounds useful for treating liver diseases ABIONYX PHARMA SA (FR) 2023-04-25 US disclosed
US-20220363632-A1 Compounds Useful for Treating Liver Diseases ABIONYX PHARMA SA (FR) 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199575-A1 COMPOUNDS USEFUL FOR TREATING LIVER DISEASES SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-11634387-B2 Compounds useful for treating liver diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20250333379-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885
US-20220363632-A1 Compounds Useful for Treating Liver Diseases SLC10A1, FABP1, CPT1A PPARD 332/4885PPARA 94/4885PPARG 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.